ClinicalTrials.gg
RecruitingNCT07623057Updated Oct 21, 2026

A Study Testing the Safety and Effects of FB102 in Healthy Volunteers

A Phase 1 interventional study of FB102 Single dose - Part A and FB102 Multiple doses - Part B in Healthy Volunteer, sponsored by Forte Biosciences, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Forte Biosciences, Inc. (part of argenx) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 21, 2026Study completion movedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this Phase 1 trial is to evaluate the safety and effects of FB-102 in healthy volunteers following single and multiple doses.

Read the detailed description

FB-102 will be administered as either a single dose (Part A) or multiple doses (Parts B and C), compared with a placebo control.

Part A (single dose), participants will receive single dose FB102 will be administered as a single dose.

Part B (multiple dose), participants will receive multiple doses of FB-102 or placebo.

Part C (multiple dose), participants will receive multiple doses of FB-102 or placebo.

Participants may participate in an Optional Extension Period during which additional blood draws for PK, PD, and immunogenicity assessments will be obtained, and AEs will continue to be monitored for approximately 15 weeks. IMP will not be administered during the Optional Extension Period.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Forte Biosciences, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

First submitted before Forte Biosciences, Inc. became part of argenx.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) between 18.0 and 32.0 kg/m2, inclusive, at Screening.
  2. Weight ≥50 kg and ≤100kg.
  3. Men are required to agree to practice true abstinence; be surgically sterilized (performed at least 6 months prior and documented to no longer produce sperm - verbal confirmation through medical history review acceptable); or agree to use a condom plus effective for their female partner if of , from Screening and for at least 90 days after the EOT visit and refrain from donating sperm during this period. Effective contraception includes established use of hormonal contraception beginning at least 30 days prior to the Screening visit; or placement of an intrauterine device or intrauterine system. These contraception requirements do not apply if the male participant is in an exclusively same sex relationship; sperm donation prohibitions apply.
  4. Women are eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions apply:

    1. Not of childbearing potential, defined as surgically sterile (hysterectomy, bilateral salpingectomy, tubal ligation or bilateral oophorectomy - verbal confirmation through medical history review is acceptable).
    2. (no menses for 12 months and confirmed by follicle-stimulating hormone [FSH] level ≥40 mlU/mL).
    3. Of childbearing potential and agree to practice true abstinence or agree to use a highly effective method of contraception consistently from 30 days prior to the Screening visit until the EOT visit and are required to agree not to donate ova during the trial and for 90 days after the EOT visit.

Exclusion criteria

Exclusion Criteria:

  1. Any medical condition allergy infection or condition as determined by the Investigator except cured basal or squamous cell skin cancer.
  2. Alkaline phosphatase (ALP), (AST), alanine transaminase (ALT), and/or total >1.5× the (ULN). Participants with bilirubin >2× ULN that have a documented diagnosis of Gilbert's syndrome can be enrolled at the Investigator's discretion.
  3. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer considered treated and cured), treated or untreated, within 5 years before Screening, regardless of whether there is no evidence of local recurrence or .
  4. Positive for surface antigen (HBsAg), anti- virus (HCV) antibodies, anti- (HIV) 1 and 2 antibodies, or interferon-gamma release assay (IGRA) for tuberculosis.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    FB102 Single dose - Part A

    Part A (single ascending dose, SAD), FB102 will be administered as a single dose.

    Biological: FB102 Single dose - Part A

  • Experimental
    FB102 Multiple dose - Part B

    Part B (multiple ascending dose, MAD), FB102 will be administered once weekly for 4 doses.

    Biological: FB102 Multiple doses - Part B

  • Placebo comparator
    FB102 Placebo

    The placebo will be administered on the same schedule as the corresponding FB-102 cohort.

    Drug: FB102 Placebo

  • Experimental
    FB102 Multiple dose - Part C

    Part C (multiple dose), FB102 will be administered once every 2 weeks for 4 doses.

    Biological: FB102 Multiple doses - Part C

Interventions

  • FB102 will be administered as a single dose

    Also known as: Healthy Volunteer

  • FB102 will be administered once weekly for 4 doses.

    Also known as: Healthy Volunteer

  • DrugFB102 Placebo

    Matching placebo identical to FB102 formulation but without the active pharmaceutical ingredient

    Also known as: Healthy Volunteer

  • FB102 will be administered once every 2 weeks for 4 doses.

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and relationship to treatment of treatment-emergent adverse events (TEAEs)

    Time frame: From day 1 to Day 85 (End of treatment visit)

  2. Incidence, severity, and relationship to treatment of SAEs

    Time frame: From day 1 to Day 85 (End of treatment visit)

Secondary outcomes

  1. Plasma PK parameters for single dose- maximum serum concentration (Cmax)

    Time frame: Day 1,2,3,4,5,8,15,22,36,50,85

  2. Plasma PK parameters for single dose- time to maximum concentration (Tmax)

    Time frame: Day 1,2,3,4,5,8,15,22,36,50,85

  3. Plasma PK parameters for Multiple dose- maximum serum concentration (Cmax)

    Time frame: Days 1 and 22

  4. Plasma PK parameters for Multiple dose- time to maximum concentration (Tmax)

    Time frame: Days 1 and 22

07

Study locations

2 of 2 sites recruiting
  • University of Sunshine Coast, Morayfield
    Eastwood, Queensland 4556, Australia
    Recruiting
    • Dr Indika P Leelasena · Contact08 8361 3222
    • Dr Indika P Leelasena · Principal investigator
  • University of Sunshine Coast Clinical Trials, Maroochydore
    Maroochydore, Queensland 4558, Australia
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2026 (actual). Primary completion is estimated for Feb 2027, 8 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Jun 2027, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Jun 2027was Feb 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Feb 2027→Jun 2027
Oct 21, 2026
Enrollment
48→64
Oct 21, 2026
Interventions
Added Biological: FB102 Single dose - Part A·Biological: FB102 Multiple doses - Part B·Biological: FB102 Multiple doses - Part C; removed Drug: FB102 Single dose·Drug: FB102 Multiple doses. Arm changed FB102 Single dose→FB102 Single dose - Part A; FB102 Multiple dose→FB102 Multiple dose - Part B. Arms added: FB102 Multiple dose - Part C
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Study completion Feb 2027→Jun 2027
    Enrollment 48→64
    Interventions Added Biological: FB102 Single dose - Part A·Biological: FB102 Multiple doses - Part B·Biological: FB102 Multiple doses - Part C; removed Drug: FB102 Single dose·Drug: FB102 Multiple doses. Arm changed FB102 Single dose→FB102 Single dose - Part A; FB102 Multiple dose→FB102 Multiple dose - Part B. Arms added: FB102 Multiple dose - Part C
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07623057
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jun 23, 2026
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Alistair Mallard
Contact
amallard@usc.edu.au
+61 7 5409 8644
Dr. Indika P Leelasena
principal investigator · University of the sunshine coast clinical trials, Morayfield

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FB102

Start the discussion